A prospective, non-interventional study to determine disease burden, current treatment schedule and use of clinical resources in patients with H1-antihistamine-refractory in real-world setting
Latest Information Update: 19 Nov 2021
At a glance
- Drugs Omalizumab (Primary)
- Indications Chronic urticaria
- Focus Therapeutic Use
- Acronyms AWARE
- 19 Nov 2021 New trial record